Ananda Pharma PLC - Ananda Pharma Appoints Viridian Capital Advisors
Announcement provided by
Ananda Pharma Plc · ANA03/02/2025 07:00

03 February 2025
ANANDA PHARMA PLC
("Ananda" or the "Company")
Ananda Pharma Appoints Viridian Capital Advisors to Advance U.S. Market Strategy
Ananda Pharma plc (AQSE: ANA), a Company focused on the development of cannabinoid-based therapies for the treatment of a range of complex conditions, today announces the appointment of Viridian Capital Advisors with immediate effect.
Viridian Capital Advisors (https://www.viridianca.com/) is a leading
Commenting on the appointment, Melissa, CEO of Ananda Pharma, said:
"We are delighted to partner with Viridian Capital Advisors. Their proven track record in the cannabis sector and extensive network within the
To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:
· Investor Hub:
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn: https://www.linkedin.com/company/anandapharma
· X: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA PHARMA PLC |
+44 (0)7463 686 497 |
|
|
Chief Executive Officer |
|
Melissa Sturgess |
|
|
|
Finance Director |
|
Jeremy Sturgess-Smith |
|
|
|
SP ANGEL CORPORATE FINANCE LLP |
+44 (0)20 3470 0470 |
|
|
Corporate Finance |
|
Richard Morrison |
|
|
|
Corporate Broking |
|
Abigail Wayne |
|
Rob Rees |
|
Yellow Jersey PR (media enquiries) Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 |
About Ananda Pharma
Ananda is an AQSE-listed life sciences company focused on the research and clinical development of cannabinoid therapies for a range of complex conditions.
For more information, please visit: www.anandapharma.co.uk
https://investors.anandapharma.co.uk/link/pegVZy
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.